In the 72-week STEP UP trial, in adults with obesity along with diet and exercise, Wegovy HD (semaglutide) injection 7.2 mg significantly reduced body weight 1 * Analysis of all patients regardless of if they stayed on treatment 7 Co-primary end point: Percent change in body weight 1* Co-primary end point: Reduction in body weight of 5% 1 * Proportion of patients achieving 5% weight loss at 72 weeks * Confirmatory secondary end points (week 72) 1 * 10% weight loss: 79.8% Wegovy HD vs 20.3% placebo 15% weight loss: 63.8% Wegovy HD vs 7.5% placebo 20% weight loss: 45.5% Wegovy HD vs 2.8% placebo ~1 in 3 people (31.2%) of patients achieved 7 * vs 0% of patients with placebo If all patients stayed on treatment 7 20.7% mean weight loss with Wegovy HD vs 2.4% (6 lb) placebo at 72 weeks, in an idealized scenario estimating efficacy if patients remained on treatment for the duration of the trial and used no other weight-loss therapies 7 Mean baseline body weight: Wegovy HD=247.8 lb
Benefits Beyond Sugar Management and Weight Loss Current Indications for Semaglutide: Glucose control in adults with type 2 diabetes Reduced risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease Obesity in adults Reduced risk of kidney decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Additional Semaglutide Studies: Reducing fatty liver disease Use in adults and pediatric patients aged 12 years and older with obesity Reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight Semaglutide oral tablets for type 2 diabetes Current Indications for Tirzepatide: Glucose control in adults with type 2 diabetes Obesity in adults, or overweight adults with at least one weight-related comorbidity Moderate to severe obstructive sleep apnea in adults with obesity Additional Tirzepatide Studies: Reducing fatty liver disease Improving osteoarthritis in the knees Use in adolescents with obesity or overweight with weight-related comorbidities Use in people with overweight or obesity and chronic kidney disease with or without type 2 diabetes Both semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are being studied for additional health benefits beyond blood sugar management and weight loss
These effects on digestive motility mean that intestinal contents move more slowly, potentially allowing more time for bacterial metabolism of sulfur compounds
The resultant inappropriately elevated glucagon levels exacerbates the metabolic defects due to insulin deficiency (see below)
More significant tissue repair and healing is typically observed at 36 weeks
Products whose only remaining Orange Book-listed patents are device-only claims may face earlier generic competition than financial models currently assume
